This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
^Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (in Chinese) 34 (11): 711–5. PMID16536313.
^Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M et al. (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID12527929.
^ abAizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K et al. (Jan 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry272 (4): 2042–5. doi:10.1074/jbc.272.4.2042. PMID8999898.
Schneider C, Hübinger G (Jul 2002). "Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family". Leukemia & Lymphoma43 (7): 1355–66. doi:10.1080/10428190290033288. PMID12389614.
Horie R, Higashihara M, Watanabe T (Jan 2003). "Hodgkin's lymphoma and CD30 signal transduction". International Journal of Hematology77 (1): 37–47. doi:10.1007/BF02982601. PMID12568298.
Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H (Feb 1992). "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease". Cell68 (3): 421–7. doi:10.1016/0092-8674(92)90180-K. PMID1310894.
Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay". European Journal of Immunology19 (1): 157–62. doi:10.1002/eji.1830190125. PMID2537734.
Stein H, Gerdes J, Schwab U, Lemke H, Mason DY, Ziegler A et al. (Oct 1982). "Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". International Journal of Cancer. Journal International Du Cancer30 (4): 445–59. doi:10.1002/ijc.2910300411. PMID6754630.
Jung W, Krueger S, Renner C, Gause A, Sahin U, Trümper L et al. (Dec 1994). "Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Molecular Immunology31 (17): 1329–34. doi:10.1016/0161-5890(94)90051-5. PMID7527901.
Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S (Jun 1994). "Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3". Oncogene9 (6): 1567–74. PMID8183550.
Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB (May 1996). "CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins". The Journal of Biological Chemistry271 (22): 12852–8. doi:10.1074/jbc.271.22.12852. PMID8662842.
Horie R, Ito K, Tatewaki M, Nagai M, Aizawa S, Higashihara M et al. (Oct 1996). "A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages". Blood88 (7): 2422–32. PMID8839832.
Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K et al. (Jan 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry272 (4): 2042–5. doi:10.1074/jbc.272.4.2042. PMID8999898.
Boucher LM, Marengère LE, Lu Y, Thukral S, Mak TW (Apr 1997). "Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily". Biochemical and Biophysical Research Communications233 (3): 592–600. doi:10.1006/bbrc.1997.6509. PMID9168896.
Mizushima S, Fujita M, Ishida T, Azuma S, Kato K, Hirai M et al. (Jan 1998). "Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5)". Gene207 (2): 135–40. doi:10.1016/S0378-1119(97)00616-1. PMID9511754.
Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR (Mar 1999). "Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells". Nature398 (6725): 341–4. doi:10.1038/18692. PMID10192335.